Skip to main content
Top

Open Access 05-04-2024 | Ovarian Cancer | Original Paper

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

Authors: Camilla Sköld, Sara Corvigno, Hanna Dahlstrand, Gunilla Enblad, Artur Mezheyeuski, Inger Sundström-Poromaa, Karin Stålberg, Anna Tolf, Ingrid Glimelius, Anthoula Koliadi

Published in: Cancer Causes & Control

Login to get access

Abstract

Purpose

High-grade serous ovarian cancer (HGSC) is the most common ovarian cancer subtype. Parity is an important risk-reducing factor, but the underlying mechanism behind the protective effect is unclear. Our aim was to study if the expression of hormones and proteins involved in pregnancy were affected by the woman’s parity status, and if they may be associated with tumor stage and survival.

Methods

We evaluated expression of progesterone receptor (PR), progesterone receptor membrane component 1 (PGRMC1), relaxin-2, and transforming growth factor beta 1 (TGFβ1) in tumor tissue from 92 women with HGSC parous (n = 73) and nulliparous (n = 19). Key findings were then evaluated in an independent expansion cohort of 49 patients. Survival rates by hormone/protein expression were illustrated using the Kaplan–Meier method. The independent prognostic value was tested by Cox regression, using models adjusted for established poor-prognostic factors (age at diagnosis, FIGO stage, type of surgery, and macroscopic residual tumor after surgery).

Results

HGSC tumors from parous women were PR positive (≥ 1% PR expression in tumor cells) more often than tumors from nulliparous women (42% vs. 16%; p-value 0.04), and having more children was associated with developing PR positive tumors [i.e., ≥ 3 children versus nulliparity, adjusted for age at diagnosis and stage: OR 4.31 (95% CI 1.12–19.69)]. A similar result was seen in the expansion cohort. Parity status had no impact on expression of PGRMC1, relaxin-2 and TGFβ1. No associations were seen with tumor stage or survival.

Conclusion

Tumors from parous women with HGSC expressed PR more often than tumors from nulliparous women, indicating that pregnancies might possibly have a long-lasting impact on ovarian cancer development.
Appendix
Available only for authorised users
Literature
1.
go back to reference Danckert BFJ, Engholm G, Hansen HL, Johannesen TB, Khan S, Køtlum JE, Ólafsdóttir E, Schmidt LKH, Virtanen A, Storm HH (2019) NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.2 2019. Danckert BFJ, Engholm G, Hansen HL, Johannesen TB, Khan S, Køtlum JE, Ólafsdóttir E, Schmidt LKH, Virtanen A, Storm HH (2019) NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.2 2019.
2.
go back to reference Society AC (2018) Cancer facts & figures 2018. American Cancer Society, Atlanta, p 2018 Society AC (2018) Cancer facts & figures 2018. American Cancer Society, Atlanta, p 2018
3.
go back to reference Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV et al (2016) Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol 34(24):2888–2898CrossRefPubMedPubMedCentral Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV et al (2016) Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol 34(24):2888–2898CrossRefPubMedPubMedCentral
4.
go back to reference Skold C, Bjorge T, Ekbom A, Engeland A, Gissler M, Grotmol T et al (2018) Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women. Int J Cancer 143(8):1858–1867CrossRefPubMedPubMedCentral Skold C, Bjorge T, Ekbom A, Engeland A, Gissler M, Grotmol T et al (2018) Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women. Int J Cancer 143(8):1858–1867CrossRefPubMedPubMedCentral
5.
go back to reference Schuler S, Ponnath M, Engel J, Ortmann O (2013) Ovarian epithelial tumors and reproductive factors: a systematic review. Arch Gynecol Obstet 287(6):1187–1204CrossRefPubMed Schuler S, Ponnath M, Engel J, Ortmann O (2013) Ovarian epithelial tumors and reproductive factors: a systematic review. Arch Gynecol Obstet 287(6):1187–1204CrossRefPubMed
6.
go back to reference Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I et al (1994) Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344(8932):1250–1254CrossRefPubMed Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I et al (1994) Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344(8932):1250–1254CrossRefPubMed
7.
go back to reference Bu SZ, Yin DL, Ren XH, Jiang LZ, Wu ZJ, Gao QR et al (1997) Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 79(10):1944–1950CrossRefPubMed Bu SZ, Yin DL, Ren XH, Jiang LZ, Wu ZJ, Gao QR et al (1997) Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 79(10):1944–1950CrossRefPubMed
8.
go back to reference Murdoch WJ (1998) Perturbation of sheep ovarian surface epithelial cells by ovulation: evidence for roles of progesterone and poly(ADP-ribose) polymerase in the restoration of DNA integrity. J Endocrinol 156(3):503–508CrossRefPubMed Murdoch WJ (1998) Perturbation of sheep ovarian surface epithelial cells by ovulation: evidence for roles of progesterone and poly(ADP-ribose) polymerase in the restoration of DNA integrity. J Endocrinol 156(3):503–508CrossRefPubMed
9.
go back to reference Rodriguez GC, Barnes HJ, Anderson KE, Whitaker RS, Berchuck A, Petitte JN et al (2013) Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen. Cancer Prev Res 6(12):1283–1292CrossRef Rodriguez GC, Barnes HJ, Anderson KE, Whitaker RS, Berchuck A, Petitte JN et al (2013) Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen. Cancer Prev Res 6(12):1283–1292CrossRef
10.
go back to reference Rodriguez GC, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, Cline M et al (2002) Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 94(1):50–60CrossRefPubMed Rodriguez GC, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, Cline M et al (2002) Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 94(1):50–60CrossRefPubMed
11.
go back to reference Rodriguez GC, Turbov J, Rosales R, Yoo J, Hunn J, Zappia KJ et al (2016) Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: an opportunity for chemoprevention. Gynecol Oncol 143(1):159–167CrossRefPubMed Rodriguez GC, Turbov J, Rosales R, Yoo J, Hunn J, Zappia KJ et al (2016) Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: an opportunity for chemoprevention. Gynecol Oncol 143(1):159–167CrossRefPubMed
12.
go back to reference Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS et al (1998) Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 5(5):271–276PubMed Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS et al (1998) Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 5(5):271–276PubMed
13.
go back to reference Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC (2002) Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 94(1):32–38CrossRefPubMed Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC (2002) Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 94(1):32–38CrossRefPubMed
14.
go back to reference Sköld C, Koliadi A, Enblad G, Stålberg K, Glimelius I (2022) Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes. Int J Cancer 150(5):773–781CrossRefPubMed Sköld C, Koliadi A, Enblad G, Stålberg K, Glimelius I (2022) Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes. Int J Cancer 150(5):773–781CrossRefPubMed
15.
go back to reference Corvigno S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, Carlson JW, Fernebro J et al (2020) High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer. Gynecol Oncol 159(3):860–868CrossRefPubMed Corvigno S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, Carlson JW, Fernebro J et al (2020) High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer. Gynecol Oncol 159(3):860–868CrossRefPubMed
16.
go back to reference Glimelius B, Melin B, Enblad G, Alafuzoff I, Beskow A, Ahlstrom H et al (2018) U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta Oncol 57(2):187–194CrossRefPubMed Glimelius B, Melin B, Enblad G, Alafuzoff I, Beskow A, Ahlstrom H et al (2018) U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta Oncol 57(2):187–194CrossRefPubMed
17.
go back to reference Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL et al (2020) Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med 144(5):545–563CrossRefPubMed Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL et al (2020) Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med 144(5):545–563CrossRefPubMed
18.
go back to reference Shafrir AL, Rice MS, Gupta M, Terry KL, Rosner BA, Tamimi RM et al (2016) The association between reproductive and hormonal factors and ovarian cancer by estrogen-alpha and progesterone receptor status. Gynecol Oncol 143(3):628–635CrossRefPubMedPubMedCentral Shafrir AL, Rice MS, Gupta M, Terry KL, Rosner BA, Tamimi RM et al (2016) The association between reproductive and hormonal factors and ovarian cancer by estrogen-alpha and progesterone receptor status. Gynecol Oncol 143(3):628–635CrossRefPubMedPubMedCentral
19.
go back to reference RStudio Team (2020) RStudio: integrated development for R. RStudio, PBC, Boston RStudio Team (2020) RStudio: integrated development for R. RStudio, PBC, Boston
20.
go back to reference Hecht JL, Kotsopoulos J, Hankinson SE, Tworoger SS (2009) Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the nurses’ health study. Cancer Epidemiol Biomarkers Prev 18(5):1624–1630CrossRefPubMedPubMedCentral Hecht JL, Kotsopoulos J, Hankinson SE, Tworoger SS (2009) Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the nurses’ health study. Cancer Epidemiol Biomarkers Prev 18(5):1624–1630CrossRefPubMedPubMedCentral
21.
go back to reference Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT et al (2013) Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol 14(9):853–862CrossRefPubMedPubMedCentral Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT et al (2013) Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol 14(9):853–862CrossRefPubMedPubMedCentral
23.
25.
go back to reference Ren P, Yu ZT, Xiu L, Wang M, Liu HM (2013) Elevated serum levels of human relaxin-2 in patients with esophageal squamous cell carcinoma. World J Gastroenterol 19(15):2412–2418CrossRefPubMedPubMedCentral Ren P, Yu ZT, Xiu L, Wang M, Liu HM (2013) Elevated serum levels of human relaxin-2 in patients with esophageal squamous cell carcinoma. World J Gastroenterol 19(15):2412–2418CrossRefPubMedPubMedCentral
26.
go back to reference Binder C, Simon A, Binder L, Hagemann T, Schulz M, Emons G et al (2004) Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Res Treat 87(2):157–166CrossRefPubMed Binder C, Simon A, Binder L, Hagemann T, Schulz M, Emons G et al (2004) Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Res Treat 87(2):157–166CrossRefPubMed
27.
go back to reference Guo X, Liu Y, Huang X, Wang Y, Qu J, Lv Y (2017) Serum relaxin as a diagnostic and prognostic marker in patients with epithelial ovarian cancer. Cancer Biomark 21(1):81–87CrossRefPubMed Guo X, Liu Y, Huang X, Wang Y, Qu J, Lv Y (2017) Serum relaxin as a diagnostic and prognostic marker in patients with epithelial ovarian cancer. Cancer Biomark 21(1):81–87CrossRefPubMed
28.
go back to reference Zhou J, Jiang W, Huang W, Ye M, Zhu X (2020) Prognostic values of transforming growth factor-beta subtypes in ovarian cancer. Biomed Res Int 2020:2170606PubMedPubMedCentral Zhou J, Jiang W, Huang W, Ye M, Zhu X (2020) Prognostic values of transforming growth factor-beta subtypes in ovarian cancer. Biomed Res Int 2020:2170606PubMedPubMedCentral
Metadata
Title
Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer
Authors
Camilla Sköld
Sara Corvigno
Hanna Dahlstrand
Gunilla Enblad
Artur Mezheyeuski
Inger Sundström-Poromaa
Karin Stålberg
Anna Tolf
Ingrid Glimelius
Anthoula Koliadi
Publication date
05-04-2024
Publisher
Springer International Publishing
Published in
Cancer Causes & Control
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-024-01876-2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine